An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype

BACKGROUND: In our previous dose-escalation study, we uncovered the maximum tolerated dose (MTD) of weekly irinotecan was escalated to 80 mg/m(2) and 65 mg/m(2) for UDP glucuronosyltransferase family 1 member A1 (UGT1A1) *1*1 and *1*28 rectal cancer patients in neoadjuvant chemoradiotherapy (nCRT)....

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yun, Shen, Yunzhu, Xu, Ye, Li, Chao, Wang, Jingwen, Gu, Weilie, Lian, Peng, Huang, Dan, Cai, Sanjun, Zhang, Zhen, Zhu, Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557009/
https://www.ncbi.nlm.nih.gov/pubmed/31217818
http://dx.doi.org/10.1177/1756284819852293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557009/
https://www.ncbi.nlm.nih.gov/pubmed/31217818
http://dx.doi.org/10.1177/1756284819852293

Ejemplares similares